Dashboard
Manage Tickers

CMMBChemomab Therapeutics Ltd.

Nasdaq chemomab.com


$ 0.80 $ 0.03 (3.58 %)    

Friday, 10-May-2024 15:53:06 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 0.839
$ 0.82
$ 0.78 x 100
$ 0.84 x 300
$ 0.80 - $ 0.82
$ 0.42 - $ 1.89
69,651
na
197.16M
$ 1.50
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-11-2023 03-31-2023 10-Q
2 03-20-2023 12-31-2022 10-K
3 11-10-2022 09-30-2022 10-Q
4 08-12-2022 06-30-2022 10-Q
5 05-12-2022 03-31-2022 10-Q
6 03-30-2022 12-31-2021 10-K
7 11-12-2021 09-30-2021 10-Q
8 08-13-2021 06-30-2021 10-Q
9 05-13-2021 03-31-2021 10-Q
10 03-09-2021 12-31-2020 10-K
11 11-16-2020 09-30-2020 10-Q
12 08-14-2020 06-30-2020 10-Q
13 05-07-2020 03-31-2020 10-Q
14 03-17-2020 12-31-2019 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chemomab-therapeutics-q1-2024-gaap-eps-028-up-from-080-yoy
Chemomab Therapeutics Q1 2024 GAAP EPS $(0...
05/09/2024 11:10:07

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share. This is a 65 percent increase over losses o...

chemomab-therapeutics-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-price-rule
Chemomab Therapeutics Granted 180-Day Exte...
05/08/2024 11:15:39

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
05/06/2024 16:31:16

oppenheimer-upgrades-chemomab-therapeutics-to-outperform-announces-6-price-target
Oppenheimer Upgrades Chemomab Therapeutics...
05/06/2024 11:52:09

Oppenheimer analyst Jeff Jones upgrades Chemomab Therapeutics (NASDAQ:CMMB) from Perform to Outperform and announces $6 pric...

chemomab-reports-new-peer-reviewed-publication-reinforcing-the-clinical-association-of-its-ccl24-target-with-disease-severity-and-mortality-in-systemic-sclerosis
Chemomab Reports New Peer-Reviewed Publica...
04/18/2024 11:11:35

Longitudinal Study of a 200+ Real-World Patient Cohort Further Validates CCL24 as a Novel Target for Systemic Sclerosis (SSc), ...

chemomab-shares-are-trading-higher-after-the-company-was-granted-a-new-european-patent-for-cm-101
Chemomab shares are trading higher after t...
03/25/2024 11:19:45

chemomab-bagged-new-european-patent-for-cm-101-its-first-in-class-monoclonal-antibody-in-phase-2-clinical-development-for-primary-sclerosing-cholangitis
Chemomab Bagged New European Patent for CM...
03/25/2024 11:09:46

Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics...

oppenheimer-maintains-perform-on-chemomab-therapeuticsto-perform
Oppenheimer Maintains Perform on Chemomab ...
03/08/2024 13:45:49

Oppenheimer analyst Jeff Jones maintains Chemomab Therapeutics (NASDAQ:CMMB) from Perform to Perform.

chemomab-therapeutics-q4-eps-026-up-from-072-yoy
Chemomab Therapeutics Q4 EPS $(0.26) Up Fr...
03/07/2024 12:06:29

Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.26) per share. This is a 63.89 percent increase over losse...

earnings-scheduled-for-march-7-2024
Earnings Scheduled For March 7, 2024
03/07/2024 09:49:44

Companies Reporting Before The Bell • CI&T (NYSE:CINT) is estimated to report quarterly earnings at $0.06 per share on rev...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
02/22/2024 13:05:56

12-health-care-stocks-moving-in-wednesdays-pre-market-session
12 Health Care Stocks Moving In Wednesday'...
02/21/2024 13:06:14

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
02/20/2024 21:31:12

whats-going-on-with-fibro-inflammatory-disease-focused-chemomab-therapeutics-on-tuesday
What's Going On With Fibro-Inflammatory Di...
02/20/2024 17:30:46

Chemomab Therapeutics' CM-101 granted new patents in Brazil and Israel, currently in Phase 2 SPRING trial for primary scler...

chemomab-wins-new-patents-for-cm-101-its-first-in-class-monoclonal-antibody-in-clinical-development-for-fibro-inflammatory-diseases
Chemomab Wins New Patents for CM-101, Its ...
02/20/2024 12:10:53

 Chemomab Therapeutics Ltd. (NASDAQ:CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutic...

chemomab-therapeutics-announced-publication-of-proteomic-analyses-that-further-demonstrate-the-unique-role-of-the-soluble-protein-ccl24-in-driving-pathologies-associated-with-the-rare-fibrotic-liver-disease-primary-sclerosing-cholangitis
Chemomab Therapeutics Announced Publicatio...
01/30/2024 12:05:35

why-mdc-holdings-shares-are-trading-higher-by-around-17-here-are-20-stocks-moving-premarket
Why M.D.C. Holdings Shares Are Trading Hig...
01/18/2024 12:52:18

Shares of M.D.C. Holdings, Inc. (NYSE: MDC) rose sharply in today’s pre-market trading. Sekisui House, Ltd. and M.D.C. Holdi...

chemomab-announces-completion-of-patient-enrollment-in-cm-101-phase-2-primary-sclerosing-cholangitis-trial-and-moves-up-expected-topline-readout-to-midyear-2024
Chemomab Announces Completion Of Patient E...
01/03/2024 12:01:36

roth-mkm-reinstates-buy-on-chemomab-therapeutics-maintains-7-price-target
Roth MKM Reinstates Buy on Chemomab Therap...
12/19/2023 14:14:05

Roth MKM analyst Dylan Dupuis reinstates Chemomab Therapeutics (NASDAQ:CMMB) with a Buy and maintains $7 price target.

why-childrens-place-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Children's Place Shares Are Trading Lo...
11/16/2023 18:11:41

Shares of The Children's Place, Inc. (NASDAQ: PLCE) moved lower during Thursday’s session following weak quarterly earnings.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION